Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease

Fig. 3

All-cause mortality in trial eligible vs trial ineligible UCC-SMART type 2 diabetes patients with cardiovascular disease. Unadjusted hazard ratios and adjusted hazard ratios with 95% CI’s are presented for eligible vs ineligible patients for each trial. Data in bold represent a statistically significant difference between eligible and ineligible patients

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840